Gabapentin is not a controlled substance at the federal level. The DEA does not schedule it under the Controlled Substances Act. However, a growing number of U.S. states have independently classified gabapentin as a Schedule V controlled substance or imposed monitoring requirements on it, driven by rising evidence of misuse, dangerous interactions with opioids, and its presence in thousands of overdose deaths each year.
Federal vs. State Classification
The distinction matters because it creates a patchwork of rules depending on where you live. As of 2024, eight U.S. jurisdictions (16%) have classified gabapentin as a Schedule V controlled substance, the lowest tier of controlled drugs. Kentucky was the first in July 2017, followed by Tennessee and West Virginia in 2018, then North Dakota, Michigan, and Virginia. Schedule V means prescriptions are tracked, refills are limited, and pharmacists must report dispensing to a state database.
Another 17 jurisdictions (33%) haven’t formally scheduled gabapentin but do require pharmacies to report gabapentin prescriptions to their Prescription Drug Monitoring Program (PDMP). Minnesota was the first to do this in 2016. In total, about half the country now monitors gabapentin prescribing in some way, even though the federal government treats it like any other non-controlled prescription medication.
Why States Started Restricting It
The push to control gabapentin came from states hardest hit by the opioid crisis. Kentucky, Tennessee, and West Virginia all cited three concerns when passing their scheduling laws: abuse potential, risk of overdose, and death. These states were seeing gabapentin show up repeatedly in toxicology reports from fatal overdoses, often alongside opioids like fentanyl.
The numbers back that concern up. In 2023, gabapentin was involved in 4,027 drug overdose deaths in the United States, representing 3.8% of all overdose fatalities. Nearly 60% of those gabapentin-involved deaths also involved fentanyl. About 22% involved methamphetamine, and roughly 21% involved cocaine. Gabapentin almost never kills on its own. The danger is what it does when combined with other substances.
How Gabapentin Amplifies Opioid Danger
Gabapentin depresses the central nervous system, and when taken with opioids, the two drugs suppress breathing in an additive way. Think of it like stacking weights on your respiratory system: each drug adds its own burden, and together they can push breathing to dangerously slow or shallow levels. Animal studies confirm gabapentin has its own dose-dependent effect on breathing, independent of opioids, and layering it on top of an opioid makes that suppression worse.
In 2019, the FDA issued a formal safety warning about this. The agency flagged serious breathing difficulties in patients using gabapentin who also take opioids, benzodiazepines, or other sedating drugs. People with lung conditions like COPD and elderly patients face the highest risk. Warning signs include unusual drowsiness, confusion, very slow or shallow breathing, bluish skin on the lips or fingertips, and unresponsiveness.
How People Misuse Gabapentin
Gabapentin produces a mild sedative, relaxing, and sometimes euphoric effect, particularly at high doses. Some people describe it as similar to a mild alcohol-like buzz. It can be misused by swallowing large quantities of pills, snorting crushed tablets, or, less commonly, dissolving and injecting them. Doses in reported misuse cases range from normal therapeutic amounts (under 3,600 mg per day) all the way up to 12,000 mg per day, more than three times the maximum prescribed dose.
A key reason gabapentin misuse grew is that for years, because it wasn’t controlled, it was much easier to obtain than opioids or benzodiazepines. Doctors prescribed it freely, refills were simple, and no monitoring system flagged patients getting it from multiple providers. People seeking to enhance the high from opioids or to manage opioid withdrawal symptoms discovered gabapentin filled both roles. That combination of easy access and dangerous utility is exactly what prompted states to act.
Gabapentin Can Cause Physical Dependence
Another reason for tighter controls is that gabapentin can produce withdrawal symptoms when stopped abruptly, a hallmark of physical dependence. In documented cases, symptoms have appeared as soon as two days after stopping the drug. Early signs include restlessness, anxiety, and nervousness. By days four and five, symptoms can escalate to confusion, agitation, disorientation, headache, and sensitivity to light.
In one well-documented case, a patient’s confusion and agitation resolved within hours of restarting gabapentin, confirming the symptoms were withdrawal-related rather than a separate condition. This pattern of physical dependence doesn’t happen to everyone, but it’s significant enough that prescribers typically taper patients off gabapentin gradually rather than stopping it all at once. The existence of a withdrawal syndrome reinforces why regulators treat gabapentin with more caution than its non-controlled federal status might suggest.
What This Means for Your Prescription
If you live in a state that has scheduled gabapentin or requires PDMP reporting, you’ll notice some practical differences. Your pharmacist will log the prescription in a state database, and your prescriber can see if you’re receiving gabapentin from other sources. Refills may be limited, and in some states you’ll need a new prescription rather than calling in for refills the way you might with a standard medication.
If you live in a state with no restrictions, gabapentin is prescribed and dispensed like any other non-controlled drug. But the trend is clearly moving toward more oversight. The number of states with some form of gabapentin monitoring has grown steadily since 2016, and that trajectory shows no sign of reversing. Whether or not gabapentin eventually gets federal scheduling remains an open question, but for now, the state-by-state approach means your experience depends entirely on where you fill your prescription.